Innovative Behavioral Solutions Maia leverages behavioral science to create evidence-based wellness programs and has developed a proprietary 'Elements of Change' framework, presenting opportunities to partner with health professionals seeking proven, scalable behavioral intervention tools.

Growing Clinical Pipeline With multiple clinical trials underway and a recently initiated Phase 3 study for Ateganosine targeting hard-to-treat cancer populations, there is potential to collaborate with biotech companies or medical institutions interested in groundbreaking cancer therapies.

Market Expansion Potential Maia aims to address a multi-billion-dollar immunotherapy market with innovative telomere-targeting treatments, creating opportunities to engage with pharmaceutical companies, venture investors, and healthcare providers focused on unmet medical needs.

Strong Leadership & Funding Activity Recent stock purchases by Maia’s CEO and directors along with private placement funding indicate solid leadership confidence and investor interest, suggesting an openness to strategic partnerships and funding opportunities.

Technology & Data Utilization Utilizing platforms like Google Analytics and Webflow indicates Maia’s commitment to digital innovation, opening doors for technology partners and service providers that can enhance their online presence and data-driven decision-making.